Royal Philips Electronics and Definiens, a Munich-based company focused on image analysis solutions, have signed a memorandum of understanding to jointly develop and market clinical decision support solutions for digital pathology.

The intended initial project between Philips and Definiens will focus on immunohistology-based breast cancer diagnostics, which includes the detection of biomarkers HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), Ki67 and p53.

“The memorandum of understanding with Definiens underpins Philips’ objective of offering a full suite of image analysis tools that can be used in combination with mainstream histological staining techniques and procedures in pathology,” says Bob van Gemen, general manager of Philips Digital Pathology.